Ovid Therapeutics, Inc. (OVID)
2.66
-0.14
(-5.00%)
USD |
NASDAQ |
Aug 31, 15:07
Ovid Therapeutics EPS Diluted (Quarterly) : -0.076 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.076 |
| March 31, 2026 | -0.1248 |
| December 31, 2025 | 0.1183 |
| September 30, 2025 | -0.171 |
| June 30, 2025 | -0.0659 |
| March 31, 2025 | -0.1441 |
| December 31, 2024 | -0.1303 |
| September 30, 2024 | -0.1973 |
| June 30, 2024 | 0.1202 |
| March 31, 2024 | -0.1654 |
| December 31, 2023 | -0.2168 |
| September 30, 2023 | -0.1593 |
| June 30, 2023 | -0.1759 |
| March 31, 2023 | -0.1895 |
| December 31, 2022 | -0.1632 |
| September 30, 2022 | -0.1699 |
| June 30, 2022 | -0.2072 |
| March 31, 2022 | -0.229 |
| December 31, 2021 | -0.369 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.1676 |
| June 30, 2021 | -0.2328 |
| March 31, 2021 | 2.532 |
| December 31, 2020 | -0.3442 |
| September 30, 2020 | -0.2765 |
| June 30, 2020 | -0.4056 |
| March 31, 2020 | -0.3661 |
| December 31, 2019 | -0.3453 |
| September 30, 2019 | -0.432 |
| June 30, 2019 | -0.3375 |
| March 31, 2019 | -0.455 |
| December 31, 2018 | -0.5236 |
| September 30, 2018 | -0.5262 |
| June 30, 2018 | -0.53 |
| March 31, 2018 | -0.5357 |
| December 31, 2017 | -0.45 |
| September 30, 2017 | -0.38 |
| June 30, 2017 | -0.57 |
| March 31, 2017 | -1.350 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.01M |
| Revenue (Quarterly) | 0.733M |
| Total Expenses (Quarterly) | 15.74M |
| Enterprise Value | 412.81M |
| Gross Profit Margin (Quarterly) | 97.82% |
| Profit Margin (Quarterly) | -2.05K% |
| Earnings Yield | -9.53% |
| Normalized Earnings Yield | -2.763 |